Bertha Madras

Last updated

Bertha Kalifon Madras is a professor of psychobiology in the Department of Psychiatry and the chair of the Division of Neurochemistry at Harvard Medical School, Harvard University. She served as associate director for public education in the division on Addictions at Harvard Medical School. Madras has published research in the areas of drug addiction (particularly the effects of cocaine), ADHD, and Parkinson's disease.

Contents

Madras earned a BSc in biochemistry with honors from McGill University in 1963. [1] [2] As a J.B. Collop Fellow of the Faculty of Medicine, she earned a PhD in biochemistry (metabolism and pharmacology, including hallucinogens) from McGill University in 1967. [1] [2] She completed postdoctoral fellowships in biochemistry at Tufts University/Cornell University Medical College (1966–1967) as well as at the Massachusetts Institute of Technology (1967–1969). [1] [2] Thereafter, she was appointed a research associate at the Massachusetts Institute of Technology (1972–1974) as well as an assistant professor in the Departments of Pharmacology and Psychiatry at the University of Toronto. [1] [2] Dr Madras joined the Harvard Medical School as an assistant professor in 1986 and was subsequently promoted to associate professor and (full) professor – with a cross-appointment to the Department of Psychiatry at the Massachusetts General Hospital. [1] Dr Madras also founded and chaired the Division of Neurochemistry at Harvard Medical School's New England Primate Research Centre – a multidisciplinary, translational research program which spans chemical design, molecular and cellular biology, behavioral biology, and brain imaging approaches. [1] She directs the Laboratory of Addiction Neurobiology, McLean Hospital, in conjunction with the Harvard Brain Science initiative. [3]

Personal life

She is married to Peter Madras and has two daughters, two sons-in-law, and five grandchildren.[ citation needed ].

Public policy work

Madras served as the deputy director for demand reduction for the White House Office of National Drug Control Policy; [4] She was nominated by President George W. Bush in July, 2005, and unanimously confirmed by the United States Senate in 2006. [5] [6] [7] In the federal budget for Medicaid reimbursement, assurances that the majority of federal employees' healthcare insurers would reimburse for these procedures, that certain State Medicaid plans would reimburse for SBI services, that the Veterans' Administration would mandate SBI for alcohol throughout the VA system, [8] and that the Federal Health Resource Services Administration (HRSA) would implement these services in the underserved populations. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]

Research

Madras has authored over 130 scientific manuscripts and book chapters, and she recently co-edited a book on the Cell Biology of Addiction. [19] Along with her collaborators, she is the recipient of 19 patents. [20]

Honours

Her co-discovery of altropane was recognized by the Association of University Technology Managers in 2006. [21]

Related Research Articles

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite it causing problems. Some definitions require evidence of dependence and withdrawal. Problematic use of alcohol has been mentioned in the earliest historical records. The World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are sometimes considered stigmatizing and to discourage seeking treatment, so diagnostic terms such as alcohol use disorder or alcohol dependence are often used instead in a clinical context.

<span class="mw-page-title-main">Substance abuse</span> Harmful use of drugs

Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods that are harmful to the individual or others. It is a form of substance-related disorder. Differing definitions of drug abuse are used in public health, medical, and criminal justice contexts. In some cases, criminal or anti-social behavior occurs when the person is under the influence of a drug, and long-term personality changes in individuals may also occur. In addition to possible physical, social, and psychological harm, the use of some drugs may also lead to criminal penalties, although these vary widely depending on the local jurisdiction.

<span class="mw-page-title-main">Office of National Drug Control Policy</span> United States government agency

The Office of National Drug Control Policy (ONDCP) is a component of the Executive Office of the President of the United States.

<span class="mw-page-title-main">Alcohol dependence</span> Medical condition

Alcohol dependence is a previous psychiatric diagnosis in which an individual is physically or psychologically dependent upon alcohol.

Commonly-cited arguments for and against the prohibition of drugs include the following:

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">Nora Volkow</span> American physician

Nora D. Volkow is a Mexican-American psychiatrist. She is currently the director of the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH).

David C. Lewis was Professor Emeritus of Medicine and Community Health and the Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies at Brown University.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite substantial harm and adverse consequences to self and others. Related terms include substance use problems and problematic drug or alcohol use.

<span class="mw-page-title-main">Addiction</span> Disorder resulting in compulsive behaviours

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in the development of addiction.

<span class="mw-page-title-main">Cannabis use disorder</span> Continued use of cannabis despite clinically significant impairment

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.

Addiction psychiatry is a medical subspecialty within psychiatry that focuses on the evaluation, diagnosis, and treatment of people who have one or more disorders related to addiction. This may include disorders involving legal and illegal drugs, gambling, sex, food, and other impulse control disorders. Addiction psychiatrists are substance use disorder experts. Growing amounts of scientific knowledge, such as the health effects and treatments for substance use disorders, have led to advancements in the field of addiction psychiatry. These advancements in understanding the neurobiology of rewarding behavior, along with federal funding, has allowed for ample opportunity for research in the discipline of addiction psychiatry. Addiction psychiatry is an expanding field, and currently there is a high demand for substance use disorder experts in both the private and public sector.

<span class="mw-page-title-main">Mark S. Gold</span>

Mark S. Gold is an American physician, academic, and researcher known for his work on the effects of opioids, cocaine, tobacco, and food on brain function and behavior. He has held academic positions as a professor of neuroscience and psychiatry and served as chair of the Department of Psychiatry at the University of Florida College of Medicine, where he established the Division of Addiction Medicine.

<span class="mw-page-title-main">Michael Botticelli</span> American public health official

Michael P. Botticelli is an American public health official who served as the director of the White House Office of National Drug Control Policy (ONDCP) from March 2014 until the end of President Obama's term. He was named acting director after the resignation of Gil Kerlikowske, and received confirmation from the United States Senate in February 2015. Prior to joining ONDCP, he worked in the Massachusetts Department of Public Health. Following completion of his service as ONDCP Director, he became the executive director of the Grayken Center for Addiction Medicine at the Boston Medical Center.

<span class="mw-page-title-main">Charles P. O'Brien</span> American research scientist, medical educator (born 1939)

Charles P. O'Brien is a research scientist, medical educator and a leading expert in the science and treatment of addiction. He is board certified in neurology, psychiatry and addiction psychiatry. He is currently the Kenneth E. Appel Professor of Psychiatry, and vice chair of psychiatry, in the Perelman School of Medicine at the University of Pennsylvania.

John R. Knight is an Associate Professor of Pediatrics at Harvard Medical School (HMS) and the Associate Director for Medical Education at the HMS Division on Addictions. In 1999, he founded the Center for Adolescent Substance Abuse Research (CeASAR) and its companion outpatient clinic, the Adolescent Substance Abuse Program (ASAP). CeASAR and ASAP were the first programs of their kind to be located at a children’s hospital. He is best known as the clinical scientist who developed and validated the CRAFFT substance abuse screen for adolescents. In 2008 he was named the inaugural incumbent of the Boston Children’s Hospital Endowed Chair in Developmental Medicine

<span class="mw-page-title-main">Elinore McCance-Katz</span> American physician, academic, and government official

Elinore F. McCance-Katz is an American physician, academic, and government official who served as Assistant Secretary of Health and Human Services for Mental Health and Substance Use from 2017 to 2021. Prior to assuming her current role, she was the chief medical officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities, and Hospitals and a professor at the Alpert Medical School at Brown University. Her nomination was supported by the American Psychiatric Association, which released a statement saying "Dr. McCance-Katz has a wealth of experience in academic and public sector settings in addressing mental health and substance use disorders."

<span class="mw-page-title-main">Keith Humphreys</span> American psychologist (born 1966)

Keith Humphreys is an American psychologist who is currently the Esther Ting Memorial Professor at Stanford University, a Senior Research Career Scientist in the Veterans Health Administration, and an Honorary Professor at the Institute of Psychiatry, King's College, London.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

Amy Janes is an American psychiatry researcher. She is chief of the Cognitive and Pharmacological Neuroimaging Unit at the National Institute on Drug Abuse's Intramural Research Program. She is known for her work using multimodal neuroimaging to examine individual differences and potential therapeutics in addictive and substance use disorders. Prior to joining NIDA, Janes was an associate professor at Harvard Medical School, working at McLean Hospital, where she founded the Functional Integration of Addiction Research Laboratory.

References

  1. 1 2 3 4 5 6 "United States of America v. Schweder, et al. (2014). "Declaration of Bertha Madras, Ph.D". Case No. 2:11-CR-00449-KJM-16, in the United States District Court – Eastern District of California. Page 2" (PDF). Archived (PDF) from the original on April 17, 2018. Retrieved August 8, 2017.
  2. 1 2 3 4 "Bertha K. Madras, PHD | McLean Hospital". Archived from the original on August 8, 2017. Retrieved August 8, 2017.
  3. ↑ "Bertha Madras". Harvard Brain Science Initiative. Archived from the original on August 10, 2022. Retrieved August 10, 2022.
  4. ↑ "Bertha Madras, Deputy Director for Demand Reduction, White House Office of National Drug Control Policy – ONDCP". Archived from the original on August 7, 2007. Retrieved 2008-01-15.
  5. ↑ "Office of National Drug Control Policy | The White House". Whitehousedrugpolicy.gov. Archived from the original on May 16, 2008. Retrieved October 19, 2011.
  6. ↑ "Aphsa Health Services Division" (PDF). Nasmd.org. Retrieved October 19, 2011.[ permanent dead link ]
  7. ↑ http://staging.whitehousedrugpolicy.gov/about/madras.html%5B‍%5D
  8. ↑ "Archived copy". Archived from the original on May 10, 2009. Retrieved May 4, 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  9. ↑ Archived December 31, 2008, at the Wayback Machine
  10. ↑ Stephanie Whyche (May 16, 2008). "Federal Workers Get Coverage for Substance Abuse Screening". Pn.psychiatryonline.org. Archived from the original on July 29, 2012. Retrieved October 19, 2011.
  11. ↑ "National strategy focuses on screening: ONDCP demand reduction chief urges early intervention. (Office of National Drug Control Policy)". Alcoholism & Drug Abuse Weekly. February 19, 2007. Archived from the original on October 16, 2012. Retrieved April 13, 2009.
  12. ↑ Tim Caron; Matt Gever; Allison Colker (July 15, 2008). "NCSL Substance Abuse Snapshot, July 15, 2008". Ncsl.org. Archived from the original on September 8, 2012. Retrieved October 19, 2011.
  13. ↑ "National Institute on Drug Abuse to Unveil NIDAMED, Physicians' Outreach Initiative, April 6, 2009 News Release – National Institutes of Health (NIH)". Nih.gov. Archived from the original on February 18, 2012. Retrieved October 19, 2011.
  14. ↑ "Instituto De Salud Del Estado De México". Salud.edomexico.gob.mx. Archived from the original on October 7, 2011. Retrieved October 19, 2011.
  15. ↑ "Addictologia Hungarica – What Works to Reduce Drug Use". Archived from the original on January 23, 2008.
  16. ↑ Madras, BK; Compton, WM; Avula, D; Stegbauer, T; Stein, JB; Clark, HW (January 2009). "Drug and Alcohol Dependence : Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later". Drug Alcohol Depend. 99 (1–3): 280–95. doi:10.1016/j.drugalcdep.2008.08.003. PMC   2760304 . PMID   18929451.
  17. ↑ Madras, BK; Compton, WM; Avula, D; Stegbauer, T; Stein, JB; Clark, HW (January 2009). "Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later". Drug Alcohol Depend. 99 (1–3): 280–95. doi:10.1016/j.drugalcdep.2008.08.003. PMC   2760304 . PMID   18929451.
  18. ↑ Bertha K. Madras: Office of National Drug Control Policy: A scientist in drug policy in Annals of the New York Academy of Sciences, 1187: Addiction Reviews 2; pages 370–402, 2010.
  19. ↑ Madras BK. Introduction to "Cell Biology of Addiction". Editors: Madras BK, Colvis CM, Pollack JD, Rutter JL, Shurtleff D, von Zastrow M, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 1–12, 2006.
  20. ↑ "United States Patent and Trademark Office". Uspto.gov. December 1, 1994. Archived from the original on February 1, 2018. Retrieved October 19, 2011.
  21. ↑ Association of University Technology Managers 2006 Better World Reports: "Technology Transfer Stories: 25 Innovations That Changed the World" [ dead link ]

PubMed search for articles by Bertha Madras

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.